RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jorge Duconge to Antibodies, Monoclonal

This is a "connection" page, showing publications Jorge Duconge has written about Antibodies, Monoclonal.
Connection Strength

1.043
  1. Ducong? J, Merino N, Alvarez D, Beausoleil I, Fern?ndez-S?nchez E, Rodr?guez L, Burt AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J. 2008 Mar; 27(1):35-41.
    View in: PubMed
    Score: 0.276
  2. Ducong? J, Fern?ndez-S?nchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86.
    View in: PubMed
    Score: 0.211
  3. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fern?ndez-S?nchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70.
    View in: PubMed
    Score: 0.208
  4. Duconge J, Fern?ndez-S?nchez E, Mac?as A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5.
    View in: PubMed
    Score: 0.183
  5. Fernandez-S?nchez E, Ducong? J, Castillo R, Garcia I, Beausoleil I, Mac?as A. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol. 2002 Jan; 54(1):59-64.
    View in: PubMed
    Score: 0.045
  6. Morales AA, Ducong? J, Alvarez-Ruiz D, Becquer-Viart ML, N??ez-Gandolff G, Fern?ndez E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206.
    View in: PubMed
    Score: 0.039
  7. Morales AA, N??ez-Gandolff G, P?rez NP, V?liz BC, Caballero-Torres I, Ducong? J, Fern?ndez E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl Med Biol. 1999 Aug; 26(6):717-23.
    View in: PubMed
    Score: 0.038
  8. Iznaga Escobar N, Morales AM, Ducong? J, Torres IC, Fern?ndez E, G?mez JA. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998 Jan; 25(1):17-23.
    View in: PubMed
    Score: 0.034
  9. Morales-Morales A, Ducong? J, Caballero-Torres I, N??ez-Gandolff G, Fern?ndez E, Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support